Chirality in the new generation of antidepressants: Stereoselective analysis of the enantiomers of mirtazapine, N-demethylmirtazapine, and 8-hydroxymirtazapine by LC-MS

Therapeutic Drug Monitoring

Volumn 26, Issue 4, 2004, Pages 366-374

  Paus, Erik ^a   Jonzier Perey, Michèle ^a   Cochard, Nathalie ^a   Eap, Chin B ^a   Baumann, Pierre ^a  

^a DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

Author keywords

Antidepressants; Chiral analysis; Depressive patients; Enantiomers; LC MS; Mirtazapine; Plasma

Indexed keywords

8 HYDROXYMIRTAZAPINE; ACETYLSALICYLIC ACID; AMILORIDE PLUS HYDROCHLOROTHIAZIDE; AMOXICILLIN; ANTIDEPRESSANT AGENT; ATENOLOL; CLOMETHIAZOLE; CLORAZEPATE; CLOZAPINE; CYTOCHROME P450 2D6; FLUOXETINE; FLURAZEPAM; FLUVOXAMINE; GLUCURONIDE; GLYCERYL TRINITRATE; LEVOTHYROXINE; LITHIUM; MIDAZOLAM; MIRTAZAPINE; MORPHINE; N NORMIRTAZAPINE; OLANZAPINE; PARACETAMOL; PIZOTIFEN; REMOXIPRIDE; THIORIDAZINE; TRAMADOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; ZOPICLONE;

ACCURACY; ADULT; AGED; ARTICLE; CALIBRATION; CHIRALITY; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG CONJUGATION; DRUG DETERMINATION; DRUG GLUCURONIDATION; ENANTIOMER; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID CHROMATOGRAPHY; LIQUID LIQUID EXTRACTION; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; STEREOCHEMISTRY;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; MIANSERIN; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; STEREOISOMERISM;

EID: 3342998264     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200408000-00005     Document Type: Article

References (19)

1. Holm KJ, Markham A. Mirtazapine-a review of its use in major depression. Drugs. 1999;57:607-631.
2. Kelder J, Funke C, de Boer T, et al. A comparison of the physicochemical and biological properties of mirtazapine and mianserin. J Pharm Pharmacol. 1997;49:403-411.
3. Davis R, Wilde MI. Mirtazapine-A review of its pharmacology and therapeutic potential in the management of major depression. CNS Drugs. 1996;5:389-402.
4. Timmer CJ, Sitsen JMA, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet. 2000;38:461-474.
5. de Boer T. The pharmacologic profile of mirtazapine. J Clin Psychiatry. 1996;57(suppl. 4):19-25.
6. McGrath C, Burrows GD, Norman TR. Neurochemical effects of the enantiomers of mirtazapine in normal rats. Eur J Pharmacol. 1998;356:121-126.
7. Haddjeri N, Blier P, De Montigny C. Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine. Int Clin Psychopharmacol. 1995;10(suppl. 4):11-17.
8. Haddjeri N, Blier P, De Montigny C. Effect of the alpha-2 adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain. J Pharmacol Exp Ther. 1996;277:861-871.
9. Delbressine LPC, Moonen MEG, Kaspersen FM, et al. Pharmacokinetics and biotransformation of mirtazapine in human volunteers. Clin Drug Invest. 1998;15:45-55.
10. Dahl ML, Voortman G, Alm C, et al. In vitro and in vivo studies on the disposition of mirtazapine in humans. Clin Drug Invest. 1997;13:37-46.
11. Maris FA, Dingler E, Niehues S. High-performance liquid chromatographic assay with fluorescence detection for the routine monitoring of the antidepressant mirtazapine and its demethyl metabolite in human plasma. J Chromatogr. 1999;721:309-316.
12. Paanakker JE, van Hal HJ. Capillary gas chromatographic assay for the routine monitoring of the antidepressant mepirzepine in human plasma. J Chromatogr. 1987;417:203-207.
13. Dodd S, Burrows GD, Norman TR. Chiral determination of mirtazapine in human blood plasma by high-performance liquid chromatography. J Chromatogr B. 2000;748:439-443.
14. 2-selective adrenoceptor antagonist org 3770 (mirtazapine, remeron) enhances noradrenergic and serotonergic transmission. Hum Psychopharmacol Clin Exp. 1995;10: S107-S118.
15. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet. 1996;31:444-469.
16. von Bahr C, Spina E, Birgersson C, et al. Inhibition of desmethylimipramine 2-hydroxylation by drugs in human liver microsomes. Biochem Pharmacol. 1985;34:2501-2505.
17. Ko JW, Sukhova N, Thacker D, et al. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos. 1997;25:853-862.
18. Andersson T, Hassan-Alin M, Hasselgren G, et al. Drug interaction studies with esomeprazole, the (S)-isomer of omeprazole. Clin Pharmacokinet. 2001;40:523-537.
19. Störmer E, Von Moltke LL, Greenblatt DJ. Scaling drug biotransformation data from cDNA-expressed cytochrome P-450 to human liver: a comparison of relative activity factors and human liver abundance in studies of mirtazapine metabolism. J Pharmacol Exp Ther. 2000;295:793-801.